stereotactic ablative body radiotherapy

RADIATION3 trials

Sponsors

Sunnybrook Health Sciences Centre, British Columbia Cancer Agency, Chongqing University Cancer Hospital

Conditions

Metastatic TumorsNon-small Cell Lung CancerProstate Cancer

Unknown Phase

Hypofractionated Accelerated Radiotherapy for Low Risk Localized Prostate Cancer

CompletedNCT01578902

Sunnybrook Health Sciences CentreProstate Cancer

Start: 2006-10-31End: 2013-04-30Updated: 2020-12-17

Stereotactic Ablative Body Radiotherapy (SABR) for Oligometastases

Active, not recruitingNCT02933242

British Columbia Cancer AgencyMetastatic Tumors

Start: 2016-11-30End: 2026-07-31Updated: 2025-11-17

Efficacy and Safety of Almonertinib Combined With Stereotactic Body Radiotherapy (SBRT) in the Treatment of Non-small Cell Lung Cancer With EGFR Sensitive Mutation: a Single-arm, Open-label Clinical Trial

RecruitingNCT06481566

Chongqing University Cancer HospitalNon-small Cell Lung Cancer

Start: 2024-06-21End: 2026-06-30Target: 30Updated: 2024-09-04

Related Papers

Treatment With Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients With Cancer

JAMA Oncology2022-09-2960 citations

Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5

BMC Cancer2018-10-0425 citations

Dose-Escalated Stereotactic Body Radiation Therapy for Prostate Cancer: Quality-of-Life Comparison of Two Prospective Trials.

2016-08-2917 citations

Dose escalation of five-fraction SABR for prostate cancer: Biochemical outcome and toxicity comparison of two prospective trials.

Journal of Clinical Oncology2015-03-01